Matsushita Kenichi
Division of Cardiology, Second Department of Internal Medicine, Kyorin University School of Medicine, Tokyo 181-8611, Japan.
Stem Cells Int. 2016;2016:2892840. doi: 10.1155/2016/2892840. Epub 2016 May 29.
Metabolic syndrome is an obesity-based, complicated clinical condition that has become a global epidemic problem with a high associated risk for cardiovascular disease and mortality. Dyslipidemia, hypertension, and diabetes or glucose dysmetabolism are the major factors constituting metabolic syndrome, and these factors are interrelated and share underlying pathophysiological mechanisms. Severe obesity predisposes individuals to metabolic syndrome, and recent data suggest that mesenchymal stem cells (MSCs) contribute significantly to adipocyte generation by increasing the number of adipocytes. Accordingly, an increasing number of studies have examined the potential roles of MSCs in managing obesity and metabolic syndrome. However, despite the growing bank of experimental and clinical data, the efficacy and the safety of MSCs in the clinical setting are still to be optimized. It is thus hoped that ongoing and future studies can elucidate the roles of MSCs in metabolic syndrome and lead to MSC-based therapeutic options for affected patients. This review discusses current understanding of the relationship between MSCs and metabolic syndrome and its potential implications for patient management.
代谢综合征是一种以肥胖为基础的复杂临床病症，已成为一个全球性的流行问题，与心血管疾病和死亡率的高相关风险有关。血脂异常、高血压以及糖尿病或糖代谢异常是构成代谢综合征的主要因素，这些因素相互关联且具有共同的潜在病理生理机制。严重肥胖使个体易患代谢综合征，最近的数据表明间充质干细胞（MSCs）通过增加脂肪细胞数量对脂肪生成有显著贡献。因此，越来越多的研究探讨了MSCs在管理肥胖和代谢综合征中的潜在作用。然而，尽管实验和临床数据不断积累，但MSCs在临床环境中的疗效和安全性仍有待优化。因此，希望正在进行的和未来的研究能够阐明MSCs在代谢综合征中的作用，并为受影响的患者带来基于MSCs的治疗选择。本综述讨论了目前对MSCs与代谢综合征之间关系的理解及其对患者管理的潜在影响。
